Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TP-38 · 2 trials · 2 indications
% patients alive
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 40 mL of TP-38 at a 100 nanograms/mL concentration |
| TP38 50 ng/mL | EXPERIMENTAL | - |
| TP38 100 ng/mL | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TP-38 | DRUG | TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38. |
| TP38 | DRUG | recombinant chimeric protein |
Inclusion Criteria: The patients must fulfill all the following criteria: * Previous histologically-confirmed diagnosis of primary GBM (glioblastoma multiforme, glioma grade 4 at time of first diagnosis). * Histologically-confirmed and MRI diagnosed recurrent or progressive GBM after previous rese...
TP-38 is an investigational small molecule being studied for the treatment of glioblastoma multiforme, including recurrent glioblastoma multiforme. It is in Phase 2 clinical development for these oncology indications.
TP-38 is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with glioblastoma multiforme.
TP-38 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials for the treatment of glioblastoma multiforme.
TP-38 has been studied in two completed Phase 2 clinical trials: NCT00071539 and NCT00104091. Both trials evaluated the drug in patients with recurrent grade 4 malignant brain tumors, including glioblastoma multiforme, with a combined enrollment of 56 participants.
TP-38 is not known to have alternative names. It is a distinct investigational small molecule being developed by Teva Pharmaceutical Industries for the treatment of glioblastoma multiforme.